AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01813084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses
Study NCT03509025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jointstem
Description: JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Study NCT00877058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preventive home visit
Study NCT03417700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NW training
Description: NW training
Study NCT03417700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: training with placebo
Study NCT00877058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: senior meetings
Study NCT00827879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength at Home Couples Group
Description: A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
Study NCT00827879 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Group Therapy
Description: A general support group designed to enhance support for healthy relationship building.
Study NCT01722240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 1.8mg
Study NCT01722240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01518920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.35 mg oral solution
Study NCT01518920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.27 mg oral solution
Study NCT01518920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study NCT02653560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Study NCT02653560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium magnesium Citrate (KMgCit)
Study NCT02653560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium citrate powder
Study NCT02653560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00721773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril
Description: Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
Study NCT00721773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
Study NCT00721773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril+Valsartan
Description: Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
Study NCT00721773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
Study NCT01894581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LOVAZA
Description: Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
Study NCT01894581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LOVAZA
Description: Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
Study NCT01894581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH
Description: An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
Study NCT03417700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HICT
Description: Training and vitamin D
Study NCT01219127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Derma-PACE
Description: ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
Study NCT01840722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI-based HIV Risk Reduction
Description: As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
Study NCT03080350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual
Description: Fentanyl sublingual
Study NCT01894581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
Study NCT02367677 — intervention group
Intervention type: OTHER
Intervention: Method comparison
Study NCT01334268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte Paclitaxel-Eluting Coronary Stent System
Description: Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
Study NCT01334268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Zotarolimus-Eluting Coronary Stent System
Description: Resolute Zotarolimus-Eluting Coronary Stent System Implantation
Study NCT00121550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Study NCT00121550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clarithromycin
Study NCT04138420 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab Injection
Description: Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
Study NCT02941445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin and metformin
Study NCT02941445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT02201654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EBUS without stylet
Description: the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
Study NCT01968590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
Study NCT01988259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral approach for Laminoplasty
Description: Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
Study NCT01988259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral approach for laminoplasty
Description: Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
Study NCT01988259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subperiosteal approach for foraminotomy
Description: Unilateral subperiostal approach for single level foraminotomy
Study NCT01988259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transmuscular approach for foraminotomy
Description: Unilateral transmuscular approach for single level foraminotomy
Study NCT03712319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REM Volver a casa
Description: The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
Study NCT03712319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction program
Description: The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
Study NCT01759030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
Study NCT01759030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
Study NCT02213016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study NCT02213016 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Study NCT00289315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary (Environmental) Weight Gain Prevention
Description: School-based program that modifies the school environment to promote healthy eating and physical activity
Study NCT00289315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Secondary (Behavioral) Weight Gain Prevention
Description: School-based environmental program to promote healthy eating and physical activity in the overweight students.
Study NCT00289315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control program that does not include an active intervention for promoting healthy eating and physical activity.
Study NCT03376854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
Study NCT03376854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents
Description: Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
Study NCT03376854 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature >38°C will receive 650 mg acetaminophen and, if temperature remains >38°C, surface cooling will be initiated to return core temperature to 37-38°C.
Study NCT00463346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate 1998 mg tid
Study NCT00463346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01238679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study NCT01238679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT01798199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The training by Verve System
Study NCT03556007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Study NCT03556007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Study NCT04407000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test: Favipiravir 200 mg (LOQULAR)
Description: Test Drug
Study NCT04407000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference: Favipiravir 200 mg (Avigan)
Description: Reference Drug
Study NCT02144233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Description: The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)
Study NCT02144233 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo occlusal adjustment
Description: Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
Study NCT00087581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
Study NCT00087581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
Study NCT00087581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
Study NCT03080350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl ev
Description: Fentanyl ev
Study NCT03080350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sublingual
Description: Placebo sublingual
Study NCT03080350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ev
Description: Placebo - NaCL 0,9% ev
Study NCT04069455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Patients Reported Outcomes
Description: ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
Study NCT04084522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saturated Fat- Desi Ghee (Clarified Butter)
Description: Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
Study NCT04084522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soyabean Oil
Description: Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
Study NCT03905642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arikayce™
Description: Amikacin (aminoglycoside) in a liposomal formulation.
Study NCT03686839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMR neurofeedback training to MCI
Description: SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
Study NCT03719547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal radical hysterectomy
Description: Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
Study NCT03719547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical hysterectomy
Description: Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
Study NCT03577301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based Delivery
Description: A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.
Study NCT03577301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote Delivery
Description: A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.
Study NCT03577301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal Delivery
Description: A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based or remote intervention sessions. First MI session is in person immediately after baseline. Sessions 2-4 can be delivered in person or remotely based on youth preference.
Study NCT03719547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel lymph node biopsy
Description: Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
Study NCT03719547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Description: Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
Study NCT01920932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given intravenously (IV).
Study NCT01920932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV.
Study NCT01920932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally (PO).
Study NCT01920932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV.
Study NCT01920932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV.
Study NCT01920932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine(R)
Description: Given IV.
Study NCT01920932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously (SQ) as clinically indicated.
Study NCT01920932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.